Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Trastuzumab Neoadjuvant Therapy in HER2+ Breast Cancer
NCT01594177Phase 2Completed
- Sponsor
- GBG Forschungs
- Start
- May 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in HER2-positive breast cancer, sponsored by GBG Forschungs. Primary endpoint: Pathological Complete Response at 30 weeks. Started May 2012; status: completed.
02
Drugs
afatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01594177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01594177.